

2022 Annual Report and Industry Insights

Drug Testing Index™ and Industry Insights

▶ A comprehensive analysis of workforce drug use trends



Table of Contents

The Quest Diagnostics Drug Testing Index™ (DTI) reveals insights into patterns of drug use among the American workforce. Published annually since 1988, the Drug Testing Index examines positivity rates for workplace drugs tested by the company on behalf of employers. Quest Diagnostics publishes these findings as a public service for government, employers, policymakers, and the general public.

Analysis

Workforce Drug Test Positivity Climbs to Highest Level in 2 Decades2

Urine Drug Tests

Positivity by Combined US Workforce6
Positivity by Testing Category7
Positivity by Testing Reason8
Positivity by Drug Category10
Non-Negative Rates by Specimen
Validity Test (SVT) Category13
Non-Negative Rates by Drug/SVT Category15

Oral Fluid Tests

Positivity by Testing Category18
Positivity by Testing Reason19
Positivity by Drug Category20

Hair Drug Tests

Positivity by Testing Category21
Positivity by Testing Reason22
Positivity by Drug Category23

Positivity Rates

Post-Accident vs Pre-Employment25
2021 State Legalized Use Status – Urine Drug Tests33

3-Digit Zip Code Drug Positivity Maps35

Quest examines patterns of industry-specific workplace drug use among the American workforce38

North American Industry Classification System

Methodology39
Industry Descriptions40

Industry Insights

Overall Positivity Rates41
Positivity Rates by Drug: Marijuana42
Positivity Rates by Drug: Cocaine43
Positivity Rates by Drug: Opiates44
Positivity Rates by Drug: Amphetamines45
Positivity Rates by Drug: Amphetamine46
Positivity Rates by Drug: Methamphetamine47

Workforce Drug Test Positivity Climbs to Highest Level in 2 Decades



The rate of positive drug test results among America's workforce reached its highest rate last year since 2001 and was up more than 30% in the combined US workforce from an all-time low in 2010-2012. Based on a Quest Diagnostics® study of more than 11 million deidentified urine, hair, and oral fluid drug test results collected between January and December 2021, the annual analysis, published as the Drug Testing Index, offers revealing insights into workforce drug use as employers grapple with creating safe, healthful work environments amid an ongoing recruitment and retention crisis.

The overall positivity rate in the combined US workforce, based on nearly 9 million urine drug tests collected between January and December 2021, was up in 2021 to 4.6% compared to 4.4% in 2020 and up 31.4% from the all-time low of 3.5% just 10 years ago (2010-2012). The combined US workforce, based mostly on company-policy testing by private employers, as well as the federally mandated, safety-sensitive workforce, which includes federal employees and the transportation and nuclear power industries, and can include workers such

as pilots, truck drivers, train conductors and others required to drug test under federal legislation.

For an interactive map of the Drug Testing Index with positivity rates and trend lines by drug categories and 3-digit zip code in the United States, visit DTIDrugMap.com.

"Our Drug Testing Index reveals several notable trends, including increased drug positivity rates in the safety-sensitive workforce responsible for keeping society safe, as well as higher rates of positivity in individuals tested after on-the-job accidents," said Barry Sample, PhD, Senior Science Consultant for Quest Diagnostics.

"Employers are wrestling with significant recruitment and retention challenges as well as with maintaining safe and engaging work environments that foster positive mental and physical well-being," said Keith Ward, General Manager and Vice President, Quest Diagnostics Employer Solutions. "Our Drug Testing Index data raises important questions about what it means to be an employer committed to employee health and safety. Eager to attract talent, employers may be tempted

to lower their standards. In the process, they raise the specter of more drug-related impairment and worksite accidents that put other employees and the general public in harm's way."

The new findings were unveiled on March 30, 2022, during the Drug & Alcohol Testing Industry Association 2022 Conference in Louisville, KY.

Despite years of decline, positivity rates increased in several federally mandated, safety-sensitive workforce testing categories

After 5 years of steady declines in several drug categories, positivity rates based on urine drug tests for the federally mandated, safety-sensitive workforce increased in 2021. Of note, marijuana increased 8.9% (0.79% in 2020 to 0.86% in 2021), amphetamines increased 7.8% (0.64% in 2020 to 0.69% in 2021) and cocaine increased 5.0% (0.20% in 2020 to 0.21% in 2021).

"It is important for workers to know that certain employers are required to test for marijuana under federal law and if workers use marijuana, they can still lose their jobs," said Dr Sample. "People who use drugs during working hours or before work can still be impaired and dangerous to co-workers, the general public, and themselves."

Positivity for marijuana continues upward climb in general US workforce

Positivity rates for marijuana in the general US workforce based on more than 6 million urine tests continued an upward climb, increasing 8.3% (3.6% in 2020 versus 3.9% in 2021), the highest positivity rate ever reported in the DTI. Over 5 years, positivity for marijuana in the general US workforce increased 50% (2.6% in 2017 versus 3.9% in 2021).

Overall positivity in the federally mandated, safety-sensitive workforce based on nearly 2.7 million urine drug tests stayed even year over year (2.2% in 2020 and 2021) and was 4.8% higher than 2017 (2.1% in 2017 versus 2.2% in 2021). In the general US workforce, positivity increased 1.8% (5.5% in 2020 versus 5.6% in 2021) and was 12% higher than in 2017 (5.0% in 2017 versus 5.6% in 2021) and up each of the last 5 years.

"Workers who use intoxicating substances could cause accidents and put businesses at risk for disability and insurance claims or losing a business license," said Jenny Burke, senior director of impairment practice, National Safety Council. "Drug use affecting the work environment is a complex problem that is not going away. Employers should have the right and ability to maintain a drug-free workplace using all the tools at their disposal including oral fluid, urine, and hair testing. And those employees who do not use drugs should expect their employers to protect that right."

Overall workforce drug positivity based on oral fluid testing decreased, but increased for marijuana, methamphetamine, and cocaine

In 2021, positivity in the general US workforce based on oral fluid was 7.3%, a decline of 46.3% compared to 2020 (13.6%) and 29.8% compared to 2017 (10.4%). The drop in oral fluid-positivity (13.6% in 2020 versus 7.3% in 2021) was driven by a decline in the number of pre-employment tests that included marijuana. However, for those tests that included marijuana, the oral-fluid drug positivity rate for marijuana was 14.8% in 2021, an increase of 20.3 percent compared to 2020 (12.3%) and up 68.2% over 5 years (8.8% in 2017). At the same time, the positivity rate for cocaine increased 46.6% (0.58% in 2020 versus 0.85% in 2021), its highest spike since 2006, and methamphetamine increased 26.4% (0.53% in 2020 versus 0.67% in 2021), exhibiting year-over-year increases for the last 5 years.

Oral fluid tests generally have a shorter window of drug detection than urine, and can detect some drugs faster, in a matter of minutes versus hours. Oral fluid collection also has the advantage of being observed, making it harder to subvert the testing process.

Urine positivity rates for post-accident testing increased at a greater rate than pre-employment testing over 5 years, driven by higher positivity on post-accident tests for marijuana, cocaine, and semi-synthetic opiates.

Urine positivity rates for post-accident testing increased at a greater rate than pre-employment testing over 5 years, driven by higher positivity on post-accident tests for marijuana, cocaine, and semi-synthetic opiates

Over the last 5 years in general US workforce urine drug testing, pre-employment positivity increased 17.4% (4.6% in 2017 versus 5.4% in 2021); while post-accident positivity increased 26% (7.7% in 2017 versus 9.7% in 2021).

Similarly, in federally mandated, safety-sensitive workforce urine drug testing, pre-employment positivity increased 9.5% since 2017 (2.1% in 2017 versus 2.3% in 2021), while post-accident positivity increased 41.9% (3.1% in 2017 versus 4.4% in 2021). In 2021, the post-accident positivity as compared to pre-employment positivity was 79.6% higher (9.7% versus 5.4%) in the general US workforce and 91.3% higher (4.4% versus 2.3%) in the federally mandated, safety-sensitive workforce.

In 2021, urine post-accident testing in the US general workforce for the illicit drugs marijuana and cocaine showed the positivity rate was 63.4% and 266.7% higher, respectively, as compared to pre-employment tests. For the 2 groups of semi-synthetic opiate drugs—opiates (hydrocodone/hydromorphone) and oxycodones (oxycodone/oxymorphone)—in these tests, post-accident positivity was 316.7% and 200% higher, respectively, than in pre-employment testing.

For federally mandated, safety-sensitive workforce urine drug testing in 2021, post-accident positivity for marijuana, cocaine, opiates (hydrocodone/hydromorphone) and oxycodones (oxycodone/oxymorphone) was 63.6%, 119%, 257.1%, and 194.1% higher, respectively, as compared to pre-employment tests.

Pre-employment drug tests are meant to be a deterrent in hiring workers whose drug-use behavior may cause unsafe work conditions or poor work performance. Post-accident testing is conducted to evaluate whether drug use may have played a role in the workplace incident prompting the drug test.

“The increase in post-accident positivity is alarming and suggests more drug-associated accidents may be occurring even with employers with pre-employment drug testing in place,” Dr Sample said. “The high cost of work accidents cannot be understated. While employers often think of accidents in terms of wage and productivity losses, medical expenses, and administrative expenses, accidents also impact morale, competitiveness, and recruiting. Given that employers are in a war for talent, creating a safe, healthful work environment is critical for attracting and retaining people.”

Mixed picture for cocaine positivity in the general US workforce

Positivity for cocaine based on urine tests in the general US workforce decreased 4.5% (0.22% in 2020 versus 0.21% in 2021) and positivity for cocaine over the past 5 years declined 30% (0.30% in 2017 versus 0.21% in 2021). Positivity rates for cocaine based on urine tests in the federally mandated, safety-sensitive workforce increased 5.0% (0.20% in 2020 versus 0.21% in 2021), the first increase in 5 years.





Positivity for opiates and oxycodones in the general US workforce decreased last year and over 5 years

Positivity for opiates (codeine/morphine) based on urine drug tests in the general US workforce decreased 19% (0.21% in 2020 versus 0.17% in 2021) and 56.4% over 5 years (0.39% in 2017 versus 0.17% in 2021). Positivity for opiates (hydrocodone/hydromorphone) in the general US workforce decreased 3% (0.33% in 2020 versus 0.32% in 2021) and 37.3% over 5 years (0.51% in 2017 versus 0.32% in 2021). Positivity for oxycodones (oxycodone/oxymorphone) in the general US workforce stayed the same in 2020 and 2021 (0.29%) and decreased 52.5% over 5 years (0.61% in 2017 versus 0.29% in 2021). To see a US map depicting positivity rates for different classes of opiates and oxycodone, visit [DTIDrugMap.com](https://www.dtidrugmap.com).

Positivity for 6-AM (heroin) in the general US workforce decreased over 5 years

Positivity for 6-AM metabolite (heroin) based on urine tests in the general US workforce decreased 27.8% (0.018% in 2020 versus 0.013% in 2021) and 56.7% over 5 years (0.03% in 2017 versus 0.013% in 2021). Positivity for the 6-AM metabolite (heroin) in the federally mandated, safety-sensitive workforce decreased 37.5% (0.008% in 2020 versus 0.005% in 2021) and 73.7% over 5 years (0.019% in 2017 versus 0.005% in 2021).

The Retail Trade Industry had highest positivity among key industries

The overall positivity rate increased in 16 out of 17 industries from 2017 to 2021. The Retail Trade industry had the highest overall positivity rate in 2021, at 7%, an increase of 34.6% since 2017. This sector also experienced the only year-over-year rise in methamphetamine positivity from 2017 to 2021 of 55.6% (0.09% in 2017 to 0.14% in 2021).

Marijuana positivity increased in all industries and by double-digits in 15 from 2017 to 2021. The Accommodation and Food Service industry had the highest workforce positivity for marijuana at 7.5%, a relative increase of 114.3% over 5 years (3.5% in 2017 versus 7.5% in 2021).


In the Health Care and Social Assistance industry, results saw positivity for methamphetamine decrease year-over-year. Across the last 5 years, it decreased by 50% (0.18% in 2017 to 0.09% in 2021).

For more information about company-policy, employer-based drug testing, visit our [drug screening](#) pages on our website.



Annual Positivity Rates | *Annual Report*

Urine Drug Tests - For Combined US Workforce



Nearly 9 million tests from January to December 2021


Year	Drug Positivity Rate
1989	12.7%
1990	11.0%
1991	8.8%
1992	8.8%
1993	8.4%
1994	7.5%
1995	6.7%
1996	5.8%
1997	5.0%
1998	4.8%
1999	4.6%

Year	Drug Positivity Rate
2000	4.7%
2001	4.6%
2002	4.4%
2003	4.5%
2004	4.4%
2005	4.0%
2006	3.8%
2007	3.8%
2008	3.6%
2009	3.6%
2010	3.5%

Year	Drug Positivity Rate
2011	3.5%
2012	3.5%
2013	3.7%
2014	3.9%
2015	4.0%
2016	4.2%
2017	4.2%
2018	4.4%
2019	4.5%
2020	4.4%
2021	4.6%

Positivity Rates by Testing Category | *Annual Report*


Urine Drug Tests



Testing Category	2017	2018	2019	2020	2021
Federally Mandated, Safety-Sensitive Workforce	2.1%	2.7%	2.4%	2.2%	2.2%
General US Workforce	5.0%	5.1%	5.3%	5.5%	5.6%
Combined US Workforce	4.2%	4.4%	4.5%	4.4%	4.6%

Positivity Rates by Testing Reason | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce




Nearly 2.7 million tests from January to December 2021

Testing Reason	2017	2018	2019	2020	2021
Follow-Up	3.9%	5.3%	5.1%	4.6%	4.3%
For Cause	13.1%	13.1%	13.0%	12.7%	13.8%
Post-Accident	3.1%	4.7%	4.5%	4.3%	4.4%
Pre-Employment	2.1%	2.6%	2.4%	2.1%	2.3%
Random	1.8%	2.4%	2.2%	2.0%	1.9%
Return to Duty	3.4%	5.5%	5.0%	4.5%	4.7%

Positivity Rates by Testing Reason | *Annual Report*

Urine Drug Tests – For General US Workforce




More than 6 million tests from January to December 2021

Testing Reason	2017	2018	2019	2020	2021
Follow-Up	7.8%	8.4%	8.3%	7.1%	7.1%
For Cause	33.0%	33.7%	35.7%	34.7%	34.9%
Post-Accident	7.7%	8.4%	9.1%	9.5%	9.7%
Pre-Employment	4.6%	4.7%	4.9%	5.2%	5.4%
Random	5.6%	5.7%	5.6%	5.8%	5.8%
Return to Duty	6.4%	6.4%	6.8%	6.2%	6.3%

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
6-AM	0.019%	0.013%	0.011%	0.008%	0.005%
Amphetamines (Amphetamine/Methamphetamine)	0.68%	0.68%	0.68%	0.64%	0.69%
Cocaine	0.31%	0.28%	0.25%	0.20%	0.21%
Marijuana	0.84%	0.88%	0.88%	0.79%	0.86%
MDMA (MDMA/MDA)	0.005%	0.003%	0.003%	0.002%	0.002%
Opiates (Codeine/Morphine)	0.19%	0.15%	0.12%	0.10%	0.08%
Opiates (Hydrocodone/Hydromorphone)	0.35% ^a	0.45%	0.35%	0.30%	0.27%
Oxycodones (Oxycodone/Oxymorphone)	0.25% ^a	0.34%	0.26%	0.21%	0.20%
PCP	0.03%	0.013%	0.011%	0.011%	0.010%

^a 2017 Federal employee testing October through December.

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
6-AM	0.03%	0.03%	0.02%	0.018%	0.013%
Amphetamines (Amphetamine/Methamphetamine)	1.2%	1.2%	1.3%	1.3%	1.3%
Barbiturates	0.25%	0.22%	0.20%	0.20%	0.18%
Benzodiazepines	0.61%	0.52%	0.43%	0.39%	0.36%
Cocaine	0.30%	0.28%	0.27%	0.22%	0.21%
Marijuana	2.6%	2.8%	3.1%	3.6%	3.9%
MDMA (MDMA/MDA)	0.005%	0.006%	0.008%	0.010%	0.005%

Drug Category	2017	2018	2019	2020	2021
Methadone	0.18%	0.18%	0.16%	0.14%	0.13%
Opiates	0.39%	0.31%	0.25%	0.21%	0.17%
Opiates (Hydrocodone/Hydromorphone)	0.51%	0.50%	0.37%	0.33%	0.32%
Oxycodones (Oxycodone/Oxymorphone)	0.61%	0.43%	0.34%	0.29%	0.29%
PCP	0.013%	0.011%	0.011%	0.009%	0.008%
Propoxyphene	0.001%	0.001%	0.000%	0.001%	0.000%

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For Combined US Workforce, as a Percentage of All Such Tests




Nearly 9 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
6-AM	0.02%	0.019%	0.015%	0.011%	0.008%
Amphetamines (Amphetamine/Methamphetamine)	1.1%	1.1%	1.1%	1.1%	1.1%
Barbiturates	0.25%	0.22%	0.20%	0.20%	0.18%
Benzodiazepines	0.61%	0.52%	0.43%	0.39%	0.36%
Cocaine	0.30%	0.28%	0.26%	0.21%	0.21%
Marijuana	2.1%	2.3%	2.5%	2.7%	2.9%
MDMA (MDMA/MDA)	0.005%	0.005%	0.005%	0.006%	0.004%
Methadone	0.18%	0.18%	0.16%	0.14%	0.13%

Drug Category	2017	2018	2019	2020	2021
Opiates	0.34%	0.27%	0.22%	0.17%	0.15%
Opiates (Hydrocodone/Hydromorphone)	0.50%	0.46%	0.35%	0.31%	0.28%
Oxycodones (Oxycodone/Oxymorphone)	0.60%	0.38%	0.30%	0.24%	0.24%
PCP	0.016%	0.012%	0.011%	0.010%	0.008%
Propoxyphene	0.001%	0.001%	0.000%	0.001%	0.000%

Non-Negative Rates by Specimen Validity Test (SVT)^b Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

SVT Category	2017	2018	2019	2020	2021
Acid-Base	0.02%	0.013%	0.010%	0.009%	0.009%
Invalid	0.15%	0.27%	0.21%	0.20%	0.26%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.05%	0.019%	0.017%	0.016%	0.014%

^b Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Specimen Validity Test (SVT)^b Category | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

SVT Category	2017	2018	2019	2020	2021
Acid-Base	0.004%	0.010%	0.009%	0.009%	0.009%
Invalid	0.15%	0.21%	0.18%	0.17%	0.26%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.014%	0.014%	0.015%	0.012%	0.013%

^b Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Drug/SVT Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Non-Negatives




Nearly 70,000 non-negative test results from January to December 2021

Drug/SVT Category	2017	2018	2019	2020	2021
6-AM	0.82%	0.40%	0.40%	0.31%	0.18%
Acid-Base	1.0%	0.41%	0.34%	0.35%	0.33%
Amphetamines (Amphetamine/Methamphetamine)	29.5%	22.1%	24.3%	25.9%	26.6%
Cocaine	13.7%	9.2%	9.1%	8.1%	8.0%
Invalid	6.4%	8.7%	7.5%	7.9%	10.0%
Marijuana	36.8%	28.4%	31.5%	31.9%	33.1%
MDMA (MDMA/MDA)	0.23%	0.09%	0.09%	0.09%	0.08%
Opiates (Codeine/Morphine)	8.2%	4.7%	4.2%	3.9%	3.1%
Opiates (Hydrocodone/Hydromorphone)	-	14.2%	12.3%	12.0%	10.2%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	-	10.9%	9.3%	8.5%	7.5%
PCP	1.1%	0.41%	0.41%	0.43%	0.38%
Substituted	2.2%	0.62%	0.61%	0.65%	0.56%

Non-Negative Rates by Drug/Specimen Validity Test (SVT)^b Category | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Non-Negatives




Nearly 375,000 non-negative test results from January to December 2021

Drug/SVT Category	2017	2018	2019	2020	2021
6-AM	0.12%	0.12%	0.09%	0.08%	0.06%
Acid-Base	0.07%	0.17%	0.16%	0.15%	0.15%
Amphetamines (Amphetamine/Methamphetamine)	22.4%	22.3%	22.7%	21.5%	22.1%
Barbiturates	3.0%	2.5%	2.2%	2.0%	1.9%
Benzodiazepines	7.1%	5.8%	4.6%	3.9%	3.7%
Cocaine	5.5%	5.1%	4.7%	3.7%	3.4%
Invalid	2.7%	3.7%	3.1%	3.0%	4.3%
Marijuana	47.4%	49.3%	53.1%	57.8%	57.5%
MDMA (MDMA/MDA)	0.03%	0.04%	0.05%	0.06%	0.03%
Methadone	2.0%	1.9%	1.7%	1.4%	1.3%
Opiates	7.2%	5.6%	4.5%	3.5%	2.9%
Opiates (Hydrocodone/Hydromorphone)	-	0.91%	0.87%	0.91%	0.85%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	2.1%	2.2%	1.9%	1.6%	1.6%
PCP	0.24%	0.20%	0.20%	0.16%	0.13%
Propoxyphene	0.016%	0.010%	0.005%	0.007%	0.002%
Substituted	0.26%	0.24%	0.26%	0.21%	0.21%

^b Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Drug/SVT Category | *Annual Report*

Urine Drug Tests – For Combined US Workforce, as a Percentage of All Non-Negatives




More than 440,000 non-negative test results from January to December 2021

Drug/SVT Category	2017	2018	2019	2020	2021
6-AM	0.21%	0.17%	0.14%	0.12%	0.08%
Acid-Base	0.20%	0.21%	0.19%	0.18%	0.17%
Amphetamines (Amphetamine/Methamphetamine)	23.4%	22.3%	22.9%	22.2%	22.8%
Barbiturates	2.6%	2.0%	1.8%	1.7%	1.6%
Benzodiazepines	6.2%	4.8%	3.9%	3.3%	3.1%
Cocaine	6.5%	5.8%	5.4%	4.4%	4.1%
Invalid	3.2%	4.5%	3.8%	3.8%	5.2%
Marijuana	46.0%	45.8%	49.7%	53.6%	53.7%
MDMA (MDMA/MDA)	0.06%	0.05%	0.06%	0.07%	0.04%
Methadone	1.7%	1.6%	1.4%	1.1%	1.1%
Opiates	7.3%	5.5%	4.4%	3.6%	2.9%
Opiates (Hydrocodone/Hydromorphone)	-	3.2%	2.7%	2.7%	2.3%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	1.9%	3.7%	3.1%	2.7%	2.5%
PCP	0.35%	0.24%	0.23%	0.20%	0.17%
Propoxyphene	0.014%	0.008%	0.004%	0.006%	0.002%
Substituted	0.51%	0.31%	0.31%	0.28%	0.26%

Positivity Rates by Testing Category | *Annual Report*

Oral Fluid Drug Tests – For General US Workforce




Nearly 2 million tests from January to December 2021

Testing Category	2017	2018	2019	2020	2021
General US Workforce	10.4%	10.2%	10.5%	13.6%	7.3%

Positivity Rates by Testing Reason | *Annual Report*

Oral Fluid Drug Tests – For General US Workforce




Nearly 2 million tests from January to December 2021

Testing Reason	2017	2018	2019	2020	2021
Post-Accident	5.7%	5.8%	5.4%	5.8%	8.5%
Pre-Employment	10.6%	10.5%	10.7%	13.9%	7.1%
Random	6.1%	6.2%	6.0%	5.6%	5.5%

Positivity Rates by Drug Category | *Annual Report*

Oral Fluid Drug Tests – For General US Workforce




Nearly 2 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Amphetamine	0.66%	0.73%	0.67%	0.71%	0.80%
Cocaine/Metabolite	0.73%	0.59%	0.57%	0.58%	0.85%
Marijuana	8.8%	8.7%	9.1%	12.3%	14.8%
Methamphetamines	0.43%	0.47%	0.49%	0.53%	0.67%
Opiates	0.57%	0.44%	0.35%	0.31%	0.27%
Oxycodones	-	0.31%	0.28%	0.24%	0.24%
PCP	0.06%	0.04%	0.05%	0.04%	0.05%

Positivity Rates by Testing Category | *Annual Report*

Hair Drug Tests – For General US Workforce




More than 90,000 tests from January to December 2021

Testing Category	2017	2018	2019	2020	2021
General US Workforce	10.3%	10.9%	11.2%	12.8%	13.1%

Positivity Rates by Testing Reason | *Annual Report*

Hair Drug Tests – For General US Workforce




More than 90,000 tests from January to December 2021

Testing Reason	2017	2018	2019	2020	2021
Pre-Employment	8.9%	9.4%	9.0%	9.8%	10.1%
Random	10.6%	10.1%	12.0%	16.7%	18.3%

Positivity Rates by Drug Category | *Annual Report*

Hair Drug Tests – For General US Workforce




More than 40,000 tests from January to June 2021 – Old Technology

Drug Category	2017	2018	2019	2020	2021
Amphetamines (Methamphetamine)	2.0%	2.0%	2.4%	2.6%	2.4%
Cocaine	3.2%	3.4%	3.2%	3.2%	2.8%
Marijuana	6.4%	6.8%	7.1%	8.7%	9.8%
Opiates	0.38%	0.39%	0.32%	0.29%	0.20%
PCP	0.014%	0.016%	0.012%	0.03%	0.012%

Positivity Rates by Drug Category | *Annual Report*

Hair Drug Tests – For General US Workforce




More than 50,000 tests from June to December 2021 – New Technology

Drug Category	2021
6-AM	0.08%
Amphetamine	1.8%
Benzoyllecgonine	1.1%
Cocaine	2.7%
Marijuana	9.5%
MDA	0.03%
MDMA	0.13%

Drug Category	2021
Methamphetamine	2.1%
Opiates (Codeine/Hydrocodone)	0.37%
Opiates (Morphine/Hydromorphone)	0.06%
Oxycodone	0.60%
Oxymorphone	0.03%
PCP	0.02%

Post-Accident vs Pre-Employment Positivity Rates for Marijuana | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

Drug Category	2013	2014	2015	2016	2017	2018	2019	2020	2021
Pre-Employment (PE)	0.85%	0.88%	0.90%	0.93%	0.99%	1.0%	1.0%	0.95%	1.1%
Post-Accident (PA)	0.95%	1.0%	1.1%	1.2%	1.3%	1.5%	1.6%	1.6%	1.8%
% Difference PE vs PA	11.8%	13.6%	22.2%	29.0%	31.3%	50.0%	60.0%	68.4%	63.6%

Post-Accident vs Pre-Employment Positivity Rates for Marijuana | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

Drug Category	2013	2014	2015	2016	2017	2018	2019	2020	2021
Pre-Employment (PE)	2.0%	2.2%	2.3%	2.4%	2.6%	2.8%	3.1%	3.7%	4.1%
Post-Accident (PA)	2.7%	3.3%	3.5%	3.8%	4.2%	4.8%	5.7%	6.4%	6.7%
% Difference PE vs PA	35.0%	50.0%	52.2%	58.3%	61.5%	71.4%	83.9%	73.0%	63.4%

Post-Accident vs Pre-Employment Positivity Rates for Cocaine | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	0.34%	0.31%	0.27%	0.21%	0.21%
Post-Accident (PA)	0.52%	0.55%	0.47%	0.44%	0.46%
% Difference PE vs PA	52.9%	77.4%	74.1%	109.5%	119.0%

Post-Accident vs Pre-Employment Positivity Rates for Cocaine | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	0.25%	0.24%	0.23%	0.18%	0.18%
Post-Accident (PA)	0.63%	0.71%	0.73%	0.63%	0.66%
% Difference PE vs PA	152.0%	195.8%	217.4%	250.0%	266.7%

Post-Accident vs Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	-	0.36%	0.27%	0.22%	0.21%
Post-Accident (PA)	-	1.1%	0.89%	0.81%	0.75%
% Difference PE vs PA	-	205.6%	229.6%	268.2%	257.1%

Post-Accident vs Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	0.42%	0.35%	0.26%	0.23%	0.24%
Post-Accident (PA)	1.2%	1.2%	1.1%	0.95%	1.0%
% Difference PE vs PA	185.7%	242.9%	323.1%	313.0%	316.7%

Post-Accident vs Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




Nearly 2.7 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	-	0.30%	0.22%	0.17%	0.17%
Post-Accident (PA)	-	0.77%	0.58%	0.52%	0.50%
% Difference PE vs PA	-	156.7%	163.6%	205.9%	194.1%

Post-Accident vs Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) | *Annual Report*

Urine Drug Tests – For General US Workforce, as a Percentage of All Such Tests




More than 6 million tests from January to December 2021

Drug Category	2017	2018	2019	2020	2021
Pre-Employment (PE)	0.45%	0.35%	0.28%	0.24%	0.24%
Post-Accident (PA)	1.3%	0.95%	0.77%	0.62%	0.72%
% Difference PE vs PA	188.9%	171.4%	175.0%	158.3%	200.0%

Marijuana Positivity by 2021 State Legalized Use Status – Urine Drug Tests | *Annual Report*

For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Tests for Marijuana Metabolite




Nearly 2.7 million tests from January to December 2021

Drug Category	2013	2014	2015	2016	2017	2018	2019	2020	2021
Recreational Use	0.66%	0.71%	0.72%	0.81%	0.87%	0.93%	0.94%	0.86%	0.94%
Medical Use Only	0.70%	0.74%	0.74%	0.81%	0.85%	0.87%	0.92%	0.81%	0.85%
Neither Recreational nor Medical Use	0.64%	0.67%	0.69%	0.75%	0.83%	0.88%	0.83%	0.73%	0.79%
National	0.67%	0.71%	0.71%	0.78%	0.84%	0.88%	0.88%	0.79%	0.86%

Marijuana Positivity by 2021 State Legalized Use Status – Urine Drug Tests | *Annual Report*

For General US Workforce, as a Percentage of All Tests for Marijuana Metabolite



More than 6 million tests from January to December 2021

Drug Category	2013	2014	2015	2016	2017	2018	2019	2020	2021
Recreational Use	2.2%	2.3%	2.4%	2.6%	2.7%	3.1%	3.8%	4.4%	5.1%
Medical Use Only	1.9%	2.0%	2.1%	2.1%	2.2%	2.5%	2.8%	3.2%	3.6%
Neither Recreational nor Medical Use	2.1%	2.7%	2.6%	2.7%	2.8%	2.7%	2.7%	3.0%	3.0%
National	2.1%	2.4%	2.4%	2.5%	2.6%	2.8%	3.1%	3.6%	3.9%


3-Digit Zip Code Drug Positivity Maps

Urine Drug Tests – For Combined US Workforce


January - December 2021

For an interactive map with positivity rates and trend lines by 3-digit zip code in the United States, visit QuestDiagnostics.com/DrugMap.


Overall Positivity




6-AM Positivity




Amphetamines Positivity




Cocaine Positivity




Marijuana Positivity




Opiates (Codiene/Morphine) Positivity




Opiates (Hydrocodone/Hydromorphone) Positivity



PCP Positivity



Oxycodones Positivity





Drug Testing Index™ Industry Insights


Quest examines patterns of industry-specific workplace drug use among the American workforce

The North American Industry Classification System (NAICS) is the standard used by Federal statistical agencies of Canada, Mexico, and the US in classifying business establishments for the purpose of collecting, analyzing, and publishing statistical data related to the economy. Defining an industry using a production-oriented concept means companies with the same NAICS code share production processes and technologies when producing goods and services. Simply put, an NAICS code identifies a company's primary business activity and allows a comparison of companies in like industries across the continent.

Using a hierarchical structure, an NAICS code is a 6-digit coding system that classifies all economic activity into 20 industry sectors. 5 sectors produce goods and 15 provide some type of service. Each digit in an NAICS code gradually narrows the categories. The first 2 digits of the NAICS code indicate the industry sector—the largest business sector in which a company operates. The third digit is the subsector and the fourth digit is the industry group. The fifth digit designates the NAICS industry and the sixth and final digit designates a company's national industry.

In 1997, the Standard Industrial Classification (SIC) 4-digit system was replaced by NAICS to simplify and modernize the comparison of industries. NAICS undergoes a planned review every 5 years to ensure it remains relevant.

Our data was classified by the industry sector identifier of a company's headquarters location using the most recent system, *2017 NAICS Manual: United States*, detailing 1,057 industries. For more information, visit www.census.gov/eos/www/naics/.





North American Industry Classification System

Methodology

This report of drug use patterns by industry is based on a 5-year analysis of American companies who drug test with Quest Diagnostics. Data from more than 16 million urine drug tests include overall positivity rates by industry and by drug category for marijuana, cocaine, opiates, amphetamines, and methamphetamine.

- Data includes laboratory-based urine drug tests submitted by the general US workforce for routine testing. Rehabilitation, criminal justice, and federally mandated, safety-sensitive testing data are excluded. Positive results are tabulated prior to Medical Review Officer (MRO) evaluation
- Each company is categorized by a single NAICS code. If a company can be categorized by multiple NAICS codes, it is assigned 1 code based on its largest revenue-producing report
- An industry must meet an average annual minimum volume of at least 50,000 urine drug tests to be included in our output. 3 NAICS sectors are not included in our data due to insufficient volume. Those sectors are: Agriculture, Forestry, Fishing and Hunting (11); Management of Companies and Enterprises (55); and Arts, Entertainment and Recreation (71)
- Shifts in customers and testing volume may influence positivity rates over time
- More than 90 percent of our general US workforce urine testing volume has been categorized. Data are excluded if a company is unable to be reliably classified into a category

Industry Descriptions



21 | Mining

Activities of this sector are extracting naturally occurring mineral solids, such as coal and ore; liquid minerals, such as crude petroleum; and gases, such as natural gas; and beneficiating (eg, crushing, screening, washing, and flotation) and other preparation at the mine site, or as part of mining activity.



22 | Utilities

Activities of this sector are generating, transmitting, and/or distributing electricity, gas, steam, and water and removing sewage through a permanent infrastructure of lines, mains, and pipe.



23 | Construction

Activities of this sector are erecting buildings and other structures (including additions); heavy construction other than buildings; and alterations, reconstruction, installation, and maintenance and repairs.



31-33 | Manufacturing

Activities of this sector are the mechanical, physical, or chemical transformation of materials, substances, or components into new products.



42 | Wholesale Trade

Activities of this sector are selling or arranging for the purchase or sale of goods for resale; capital or durable nonconsumer goods; and raw and intermediate materials and supplies used in production; and providing services incidental to the sale of the merchandise.



44-45 | Retail Trade

Activities of this sector are retailing merchandise generally in small quantities, to the general public and providing services incidental to the sale of the merchandise.



48-49 | Transportation and Warehousing

Activities of this sector are providing transportation of passengers and cargo, warehousing and storing goods, scenic and sightseeing transportation, and supporting these activities.



51 | Information

Activities of this sector are distributing information and cultural products, providing the means to transmit or distribute these products as data or communications, and processing data.



52 | Finance and Insurance

Activities of this sector involve the creation, liquidation, or change in ownership of financial assets (financial transactions) and/or facilitating financial transactions.



53 | Real Estate, Rental and Leasing

Activities of this sector are renting, leasing, or otherwise allowing the use of tangible or intangible assets (except copyrighted works), and providing related services.



54 | Professional, Scientific and Technical Services

Activities of this sector are performing professional, scientific, and technical services for the operations of other organizations.



56 | Administrative Support, Waste Management and Remediation Services

Activities of this sector are performing routine support activities for the day-to-day operations of other organizations.



61 | Educational Services

Activities of this sector are providing instruction and training in a wide variety of subjects.



62 | Health Care and Social Assistance

Activities of this sector are providing health care and social assistance for individuals.



72 | Accommodation and Food Services

Activities of this sector are providing customers with lodging and/or preparing meals, snacks, and beverages for immediate consumption.



81 | Other Services (except Public Administration)

Activities of this sector are providing services not elsewhere specified, including repairs, religious activities, grantmaking, advocacy, laundry, personal care, death care, and other personal services.




92 | Public Administration

Activities of this sector are administration, management, and oversight of public programs by Federal, State, and local governments.

Source: United States Census Bureau, Office of Management and Budget

Overall Positivity Rates | *Industry Insights*

Urine Drug Tests - General US Workforce




Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	4.6%	4.9%	5.1%	6.2%	6.5%
Administrative Support, Waste Management and Remediation Services ⁵⁶	4.5%	4.6%	4.7%	5.1%	5.5%
Construction ²³	4.1%	4.1%	4.2%	4.1%	4.6%
Educational Services ⁶¹	3.1%	3.1%	3.2%	3.2%	3.5%
Finance and Insurance ⁵²	2.7%	2.6%	2.8%	3.3%	3.3%
Health Care and Social Assistance ⁶²	4.6%	4.6%	4.5%	4.8%	5.1%
Information ⁵¹	3.9%	3.6%	3.7%	3.8%	4.0%
Manufacturing ³¹⁻³³	3.5%	3.7%	3.8%	4.0%	4.5%

Industry	2017	2018	2019	2020	2021
Mining ²¹	3.8%	3.7%	3.5%	3.1%	3.7%
Other Services (except Public Administration) ⁸¹	4.6%	5.2%	5.5%	5.7%	6.6%
Professional, Scientific and Technical ⁵⁴	3.2%	3.2%	3.3%	3.8%	4.4%
Public Administration ⁹²	3.3%	3.5%	3.3%	3.3%	3.5%
Real Estate, Rental and Leasing ⁵³	4.5%	4.5%	4.8%	5.0%	5.2%
Retail Trade ⁴⁴⁻⁴⁵	5.2%	5.4%	5.5%	6.2%	7.0%
Transportation and Warehousing ⁴⁸⁻⁴⁹	3.5%	3.9%	4.0%	4.4%	5.5%
Utilities ²²	2.8%	2.9%	3.4%	3.5%	3.7%
Wholesale Trade ⁴²	4.1%	4.3%	4.5%	5.2%	5.3%

Positivity Rates by Drug: Marijuana | *Industry Insights*

Urine Drug Tests - General US Workforce




Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	3.5%	4.0%	4.8%	6.3%	7.5%
Administrative Support, Waste Management and Remediation Services ⁵⁶	2.5%	2.8%	3.1%	3.6%	4.2%
Construction ²³	2.0%	2.1%	2.2%	2.5%	2.9%
Educational Services ⁶¹	0.81%	0.92%	1.0%	1.0%	1.2%
Finance and Insurance ⁵²	1.0%	1.1%	1.4%	2.1%	2.3%
Health Care and Social Assistance ⁶²	1.9%	1.9%	2.0%	2.4%	2.9%
Information ⁵¹	2.2%	2.1%	2.2%	2.7%	3.0%
Manufacturing ³¹⁻³³	1.6%	1.8%	2.0%	2.4%	3.1%

Industry	2017	2018	2019	2020	2021
Mining ²¹	1.1%	1.2%	0.91%	0.79%	1.4%
Other Services (except Public Administration) ⁸¹	2.9%	3.5%	3.8%	3.7%	5.0%
Professional, Scientific and Technical ⁵⁴	1.4%	1.5%	1.6%	2.2%	2.8%
Public Administration ⁹²	0.98%	1.2%	1.3%	1.3%	1.4%
Real Estate, Rental and Leasing ⁵³	2.6%	2.8%	3.3%	4.0%	5.1%
Retail Trade ⁴⁴⁻⁴⁵	3.2%	3.5%	3.9%	5.0%	6.4%
Transportation and Warehousing ⁴⁸⁻⁴⁹	2.1%	2.4%	2.6%	3.8%	5.4%
Utilities ²²	1.0%	1.0%	1.6%	1.7%	2.2%
Wholesale Trade ⁴²	2.3%	2.5%	2.9%	3.8%	4.5%

(More than 16 million tests from 2017 - 2021)

Positivity Rates by Drug: Cocaine | *Industry Insights*


Urine Drug Tests - General US Workforce



Industry	2017	2018	2019	2020	2021	Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	0.31%	0.30%	0.27%	0.23%	0.20%	Mining ²¹	0.27%	0.22%	0.17%	0.16%	0.21%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.24%	0.21%	0.20%	0.17%	0.21%	Other Services (except Public Administration) ⁸¹	0.25%	0.26%	0.23%	0.17%	0.20%
Construction ²³	0.41%	0.39%	0.35%	0.32%	0.30%	Professional, Scientific and Technical ⁵⁴	0.17%	0.13%	0.12%	0.12%	0.11%
Educational Services ⁶¹	0.05%	0.05%	0.04%	0.03%	0.04%	Public Administration ⁹²	0.12%	0.14%	0.14%	0.10%	0.10%
Finance and Insurance ⁵²	0.07%	0.06%	0.06%	0.06%	0.06%	Real Estate, Rental and Leasing ⁵³	0.23%	0.22%	0.26%	0.20%	0.22%
Health Care and Social Assistance ⁶²	0.18%	0.17%	0.14%	0.13%	0.12%	Retail Trade ⁴⁴⁻⁴⁵	0.20%	0.19%	0.20%	0.18%	0.19%
Information ⁵¹	0.15%	0.13%	0.10%	0.11%	0.07%	Transportation and Warehousing ⁴⁸⁻⁴⁹	0.28%	0.27%	0.25%	0.20%	0.24%
Manufacturing ³¹⁻³³	0.20%	0.19%	0.17%	0.16%	0.19%	Utilities ²²	0.20%	0.16%	0.19%	0.13%	0.15%
						Wholesale Trade ⁴²	0.26%	0.26%	0.25%	0.26%	0.26%

Positivity Rates by Drug: Opiates | *Industry Insights*

Urine Drug Tests - General US Workforce




Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	0.34%	0.35%	0.25%	0.27%	0.22%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.27%	0.21%	0.18%	0.15%	0.14%
Construction ²³	0.32%	0.23%	0.19%	0.17%	0.13%
Educational Services ⁶¹	0.17%	0.16%	0.12%	0.12%	0.12%
Finance and Insurance ⁵²	0.23%	0.13%	0.13%	0.10%	0.10%
Health Care and Social Assistance ⁶²	0.48%	0.39%	0.33%	0.29%	0.23%
Information ⁵¹	0.27%	0.19%	0.12%	0.12%	0.11%
Manufacturing ³¹⁻³³	0.33%	0.28%	0.21%	0.18%	0.16%

Industry	2017	2018	2019	2020	2021
Mining ²¹	0.62%	0.57%	0.57%	0.48%	0.43%
Other Services (except Public Administration) ⁸¹	0.25%	0.26%	0.21%	0.25%	0.18%
Professional, Scientific and Technical ⁵⁴	0.23%	0.19%	0.15%	0.13%	0.13%
Public Administration ⁹²	0.32%	0.28%	0.21%	0.16%	0.14%
Real Estate, Rental and Leasing ⁵³	0.30%	0.27%	0.21%	0.15%	0.15%
Retail Trade ⁴⁴⁻⁴⁵	0.33%	0.26%	0.23%	0.20%	0.24%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.21%	0.17%	0.14%	0.09%	0.08%
Utilities ²²	0.29%	0.24%	0.18%	0.17%	0.18%
Wholesale Trade ⁴²	0.25%	0.20%	0.16%	0.15%	0.09%

(More than 16 million tests from 2017 - 2021)

Positivity Rates by Drug: Amphetamines (Amphetamine and Methamphetamine) | *Industry Insights*

Urine Drug Tests - General US Workforce




Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	0.72%	0.72%	0.69%	0.83%	0.80%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.97%	0.97%	0.99%	1.1%	1.1%
Construction ²³	1.0%	1.0%	1.1%	1.1%	1.2%
Educational Services ⁶¹	1.6%	1.6%	1.6%	1.7%	1.9%
Finance and Insurance ⁵²	1.0%	1.1%	1.1%	1.1%	1.1%
Health Care and Social Assistance ⁶²	1.4%	1.4%	1.4%	1.4%	1.5%
Information ⁵¹	1.0%	0.97%	1.1%	1.2%	1.2%
Manufacturing ³¹⁻³³	1.0%	1.1%	1.2%	1.1%	1.2%

Industry	2017	2018	2019	2020	2021
Mining ²¹	1.3%	1.4%	1.6%	1.4%	1.4%
Other Services (except Public Administration) ⁸¹	0.87%	0.92%	1.0%	1.4%	1.3%
Professional, Scientific and Technical ⁵⁴	1.0%	1.1%	1.2%	1.2%	1.3%
Public Administration ⁹²	1.4%	1.4%	1.3%	1.3%	1.5%
Real Estate, Rental and Leasing ⁵³	0.87%	0.88%	0.90%	0.91%	0.97%
Retail Trade ⁴⁴⁻⁴⁵	0.97%	1.0%	1.0%	1.0%	1.2%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.70%	0.74%	0.71%	0.65%	0.71%
Utilities ²²	0.96%	1.0%	1.1%	1.0%	1.1%
Wholesale Trade ⁴²	1.1%	1.0%	1.0%	0.96%	1.0%

Positivity Rates by Drug: Amphetamine | *Industry Insights*

Urine Drug Tests - General US Workforce




Industry	2017	2018	2019	2020	2021	Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	0.69%	0.68%	0.64%	0.80%	0.75%	Mining ²¹	1.3%	1.3%	1.6%	1.4%	1.4%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.94%	0.94%	0.96%	1.0%	1.0%	Other Services (except Public Administration) ⁸¹	0.85%	0.90%	1.0%	1.3%	1.3%
Construction ²³	0.97%	0.98%	1.0%	1.0%	1.1%	Professional, Scientific and Technical ⁵⁴	1.0%	1.1%	1.2%	1.2%	1.2%
Educational Services ⁶¹	1.6%	1.6%	1.6%	1.7%	1.9%	Public Administration ⁹²	1.4%	1.3%	1.3%	1.3%	1.5%
Finance and Insurance ⁵²	1.0%	1.1%	1.1%	1.0%	1.1%	Real Estate, Rental and Leasing ⁵³	0.84%	0.84%	0.86%	0.87%	0.92%
Health Care and Social Assistance ⁶²	1.3%	1.3%	1.4%	1.4%	1.5%	Retail Trade ⁴⁴⁻⁴⁵	0.95%	1.0%	0.99%	1.0%	1.1%
Information ⁵¹	1.0%	0.94%	1.1%	1.2%	1.2%	Transportation and Warehousing ⁴⁸⁻⁴⁹	0.67%	0.72%	0.69%	0.63%	0.68%
Manufacturing ³¹⁻³³	1.0%	1.1%	1.1%	1.1%	1.1%	Utilities ²²	0.95%	1.0%	1.1%	1.0%	1.1%
						Wholesale Trade ⁴²	1.0%	0.99%	0.97%	0.92%	0.97%

(More than 16 million tests from 2017 - 2021)

Positivity Rates by Drug: Methamphetamine | *Industry Insights*

Urine Drug Tests - General US Workforce



Industry	2017	2018	2019	2020	2021
Accommodation and Food Services ⁷²	0.14%	0.17%	0.18%	0.17%	0.18%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.13%	0.12%	0.13%	0.12%	0.14%
Construction ²³	0.24%	0.24%	0.24%	0.21%	0.20%
Educational Services ⁶¹	0.04%	0.04%	0.03%	0.03%	0.03%
Finance and Insurance ⁵²	0.03%	0.02%	0.03%	0.04%	0.04%
Health Care and Social Assistance ⁶²	0.18%	0.16%	0.14%	0.10%	0.09%
Information ⁵¹	0.07%	0.10%	0.11%	0.11%	0.08%
Manufacturing ³¹⁻³³	0.14%	0.14%	0.15%	0.15%	0.17%

Industry	2017	2018	2019	2020	2021
Mining ²¹	0.18%	0.14%	0.14%	0.07%	0.16%
Other Services (except Public Administration) ⁸¹	0.12%	0.13%	0.13%	0.12%	0.15%
Professional, Scientific and Technical ⁵⁴	0.08%	0.08%	0.08%	0.09%	0.09%
Public Administration ⁹²	0.07%	0.09%	0.08%	0.07%	0.07%
Real Estate, Rental and Leasing ⁵³	0.12%	0.16%	0.16%	0.14%	0.16%
Retail Trade ⁴⁴⁻⁴⁵	0.09%	0.11%	0.12%	0.13%	0.14%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.11%	0.12%	0.12%	0.11%	0.12%
Utilities ²²	0.05%	0.08%	0.07%	0.08%	0.07%
Wholesale Trade ⁴²	0.16%	0.16%	0.17%	0.14%	0.16%



About Quest Diagnostics

Quest Diagnostics helps empower people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

[QuestDiagnostics.com/DTI](https://www.questdiagnostics.com/DTI)

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved. MI11026 4/2022